Drug Trial Radar · NCT07951476
Comparing Itraconazole Alone With Itraconazole Plus Terbinafine for Adults With Resistant Tinea Corporis
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jun 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Sheikh Zayed Medical CollegeGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized controlled study will compare the effectiveness of oral itraconazole alone with a combination of oral itraconazole and terbinafine in adults with resistant tinea corporis (ringworm of the body). Resistant tinea corporis is a fungal skin infection that persists despite appropriate topical antifungal treatment or returns shortly after treatment. Eligible patients aged 18-60 years with resistant tinea corporis confirmed by potassium hydroxide (KOH) microscopy will be randomly assigned to receive either oral itraconazole alone or oral itraconazole combined with terbinafine. Treatment response will be assessed clinically and by KOH microscopy. The main purpose of the study is to determine whether the combination of itraconazole and terbinafine is more effective than itraconazole alone in achieving complete clinical and mycological cure after eight weeks of treatment. Patients who achieve treatment success will also be followed for a further four weeks to assess whether the infection returns. The study hypothesis is that there is a difference in treatment efficacy between combined itraconazole with terbinafine and itraconazole alone in patients with resistant tinea corporis.
Conditions
- Tinea Corporis
- Resistant Dermatophyte Infection
Interventions
itraconazoleDrug
out of total 104 patients, 52 patients will receive oral itraconazole 100 mg twice daily after meals for 8 weeks. Patients will receive itraconazole alone as systemic antifungal treatment for resistant tinea corporis.
Itraconazole + terbinafineDrug
out of 104 patients, 52 patients will receive oral itraconazole 100 mg twice daily after meals along with oral terbinafine 250 mg once daily for 8 weeks for the treatment of resistant tinea corporis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Efficacy at 8 WeeksTime frame: 8 weeks after initiation of treatment.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.